Chemomab Therapeutics (NASDAQ:CMMB) Given “Outperform” Rating at Oppenheimer

Oppenheimer reissued their outperform rating on shares of Chemomab Therapeutics (NASDAQ:CMMB) in a research report report published on Friday morning,Benzinga reports. The firm currently has a $11.00 target price on the stock, down from their prior target price of $13.00.

Chemomab Therapeutics Trading Down 1.5 %

Shares of NASDAQ:CMMB opened at $1.65 on Friday. The firm has a market cap of $23.69 million, a price-to-earnings ratio of -1.65 and a beta of 0.53. The stock’s 50-day moving average price is $1.55 and its two-hundred day moving average price is $1.29. Chemomab Therapeutics has a 12-month low of $0.42 and a 12-month high of $2.55.

Chemomab Therapeutics (NASDAQ:CMMB) last released its earnings results on Wednesday, August 21st. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.06). During the same period last year, the business earned ($0.72) EPS. As a group, research analysts forecast that Chemomab Therapeutics will post -0.9 earnings per share for the current fiscal year.

Institutional Trading of Chemomab Therapeutics

An institutional investor recently bought a new position in Chemomab Therapeutics stock. Sphera Funds Management LTD. purchased a new position in shares of Chemomab Therapeutics Ltd. (NASDAQ:CMMB) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 1,214,575 shares of the company’s stock, valued at approximately $1,907,000. Sphera Funds Management LTD. owned about 8.46% of Chemomab Therapeutics at the end of the most recent reporting period. 46.05% of the stock is currently owned by institutional investors and hedge funds.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).